Skip to content

Specialist brief 05 · Health & Pharmaceuticals

NHS, pharmaceutical, and European health policy signals that drive decisions.

A policy-focused read of health and pharmaceutical developments across the UK and EU. Covers pricing, access, regulatory change, and the political environment around the NHS, EMA, and key national regulators. Every issue carries the consultations and appraisals open for submission, with their closing dates.

Enquire for 10+ seats
Monthly
£24 per month
Annual
£240 per year (two months free)
Trial
14 days free
Arrives
Every Sunday evening
The Health Brief, the cover of issue 02

What arrived on Sunday.

Issue 02, sent on Sunday 27th September 2026: the headline, the bottom line, one of the week’s assessments with how likely it is, and the week ahead, quoted as sent. The full issue ran to 32 pages.

An InStone Publication
Issue 02
Sunday 27th September 2026

Health policy; distilled

UK · EU

The drug regulator is putting £20m into the evidence it will need for future treatments

The bottom line

The medicines regulator is likely to have four new regulatory science centres running, after opening a £20m competition on 22nd September. The Competition and Markets Authority has opened a home oxygen merger inquiry, with comments due by 1st October.

From the assessments

The affected meropenem batches will stay in NHS supply, with the leaflet error corrected by notice rather than recall

Highly likely · 75 to 90%Confidence: Moderate

So what. Pharmacy teams should tell prescribers and nurses that the sodium figure printed in the leaflet is wrong, especially for patients on sodium-restricted diets. Check stock against the seven batch numbers in the notice.

Where things stand

Consultations

  • Revision of guidance for reducing the risk of vulnerable groups contracting listeriosis

    Open

    Open on 23rd September. Closes on 16th December.

  • MHRA consultation on statutory fees (2026)

    Closed

    Closed on 25th September.

The week ahead

  • 1Oct

    Invitation to comment on the Vivisol and Air Liquide home oxygen merger closes

    Competition and Markets Authority

  • 19Nov

    Statutory deadline for the phase 1 decision on the home oxygen merger

    Competition and Markets Authority

An excerpt. The full issue is a 32-page PDF: every assessment with its evidence, the outlook, the week on the record, method, caveats and a linked source for every point, sent with a short covering email.

A short email to read, a full report to keep.

  1. 01

    The bottom line: the week's judgement, before the working

  2. 02

    An assessment of each development, with how likely each outcome is

  3. 03

    Where the bills, regulations and consultations we follow now stand

  4. 04

    The week ahead: consultations, appraisals and regulatory deadlines

  5. 05

    A linked source for every point

Written for

Patient advocacy groups, health charities, and NHS and ministry policy staff, alongside pharmaceutical companies and health policy consultancies.

Recent issues covered

  • The medicines regulator's £20m regulatory science centres
  • MHRA fees and the national route for marketing authorisations
  • The home oxygen merger inquiry
  • NICE appraisals, from Enhertu to lenacapavir
  • Safety alerts on patient hoists and wireless foetal monitors

Often read alongside it.

All eight specialist briefs

Specialist brief 06 · Financial Services

Regulatory and political signals across UK, EU, and international financial services.

Read about the Financial Brief

Specialist brief 08 · Human Rights & Rule of Law

How rights and rule of law frameworks are moving, and where the pressure points sit.

Read about the Rights Brief

Start with 14 days free.

Then £24 per month, and you can cancel any time. Teams of ten or more can enquire about seats.

Enquire for 10+ seats